Pankaj Puar
Vancouver, BC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodeling.
Journal: American journal of physiology. Heart and circulatory physiology
Published: September 29, 2023
Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial.
Journal: BMC cardiovascular disorders
Published: May 03, 2023
A Patient-Level Pooled Analysis of 2 Empagliflozin Trials of Left Ventricular Remodeling.
Journal: Journal of cardiac failure
Published: March 16, 2023
The association between anthropometric indicators of obesity and cardiac reverse remodelling with empagliflozin in patients with type 2 diabetes and coronary artery disease.
Journal: Diabetes, obesity & metabolism
Published: December 31, 2022
Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin.
Journal: Cardiovascular diabetology
Published: December 24, 2022
Wearable Cardiac Rhythm Monitoring Device for Detection of Postoperative Atrial Fibrillation.
Journal: The Annals of thoracic surgery
Published: December 21, 2022
Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
Journal: Circulation
Published: November 06, 2022
Generalizability of the REDUCE-IT trial to South Asians with cardiovascular disease.
Journal: Med (New York, N.Y.)
Published: October 27, 2022
Impact of diabetes duration on left ventricular mass regression with empagliflozin.
Journal: ESC heart failure
Published: October 10, 2022
Last Updated: 09/26/2026